人工智慧在临床试验中的应用：全球市场

全球临床试验人工智慧市场预计将从 2024 年的 20 亿美元和 2025 年的 24 亿美元成长到 2030 年的 65 亿美元，预测期内复合年增长率为 22.6%。

预计北美市场规模将从2024年的7.712亿美元成长至2025年的9.367亿美元，到2030年达到27亿美元，复合年增长率为23.7%。预计亚太市场规模将从2024年的3.728亿美元成长至2025年的4.679亿美元，到2030年达到16亿美元，复合年增长率为28.4%。

本报告调查了全球人工智慧在临床试验中的市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测，以及按各个细分市场和地区进行的详细分析。

目录

第一章执行摘要

• 市场展望
• 调查范围
• 市场摘要

第二章 市场概览

• 概述
• 未来展望
• 宏观经济因素
• 世界GDP成长率
• 人口统计因素
• 美国关税的影响
• 波特五力分析
• 人工智慧对临床试验市场的影响
• 用例/案例研究
• 人工智慧应用：临床试验
• 区域/国家层面的采用趋势
• 人工智慧带来的颠覆性变革趋势
• 人工智慧将如何影响产业
• 人工智慧如何影响价值链
• 市场支出和投资
• 市场支出及预测分析
• 专注于临床试验的创业投资创投

第三章 市场动态

• 市场驱动因素
• 需要加速药物研发进程
• 人工智慧驱动的临床试验
• 针对复杂临床输入的高阶资料处理
• 市场限制
• 资料隐私和安全问题
• 监理不确定性
• 高成本且技术复杂
• 市场机会
• 自适应人工智慧设计加速测试
• 人工智慧驱动的远端患者监护

第四章：监理现状

• 法律规范

第五章 新兴技术

• 概述
• 新兴技术
• 机器学习在预测分析和分层的应用
• 数位双胞胎技术
• 利用自然语言处理技术从非结构化资料中提取洞见
• 人工智慧驱动的测试设计与优化
• 区块链技术用于安全的临床资料管理
• 分散式虚拟测试平台
• 利用穿戴式科技进行远端监控
• 用于通讯协定创建的生成式人工智慧
• 将真实世界证据整合到临床试验中
• 可扩展部署的云端基础人工智慧平台
• 临床试验分析
• 摘要

第六章 市场区隔分析

• 细分市场分析
• 全球临床试验人工智慧市场（按组件划分）
• 摘要
• 软体
• 服务
• 全球人工智慧在临床试验中的市场按阶段划分
• 摘要
• 第三阶段
• 第二阶段
• 第一阶段
• 第四阶段
• 全球人工智慧在临床试验中的市场按实施类型划分
• 摘要
• 云
• 本地部署
• 混合部署
• 全球人工智慧在临床试验中的市场（按治疗领域划分）
• 摘要
• 瘤
• 感染疾病临床试验
• 神经系统疾病
• 其他的
• 全球临床试验人工智慧市场（按最终用户划分）
• 摘要
• 製药和生物技术公司
• CRO
• 研究和学术机构
• 其他最终用户
• 地理细分
• 北美洲
• 欧洲
• 亚太地区
• 中东和非洲
• 南美洲

第七章 竞争讯息

第八章 人工智慧在临床试验中的永续性：ESG视角

• 永续性趋势与人工智慧倡议
• 结论

第九章附录

• 调查方法
• 来源
• 简称
• 公司简介
• AICURE
• CONCERTAI
• DNANEXUS INC.
• INSILICO MEDICINE
• INTELLIGENCIA AI
• IQVIA
• MEDIDATA
• MERATIVE
• NVIDIA CORP.
• PHESI
• SAAMA
• TEMPUS
• TRINETX LLC
• TRIOMICS
• UNLEARN.AI INC.
• Start-Ups创业公司/市场颠覆者

The global market for Artificial Intelligence (AI) in Clinical Trials was valued at $2 billion in 2024 and is estimated to increase from $2.4 billion in 2025 to reach $6.5 billion by 2030, at a compound annual growth rate (CAGR) of 22.6% from 2025 through 2030.

The North American market for AI in Clinical Trials was valued at $771.2 million in 2024 and is estimated to increase from $936.7 million in 2025 to reach $2.7 billion by 2030, at a CAGR of 23.7% from 2025 through 2030.

The Asia-Pacific market for AI in Clinical Trials was valued at $372.8 million in 2024 and is estimated to increase from $467.9 million in 2025 to reach $1.6 billion by 2030, at a CAGR of 28.4% from 2025 through 2030.

Report Scope

The report examines trends in the global market for AI in clinical trials. It segments the global market by component, phase, deployment mode, therapeutic area and end user. It also provides insights into key emerging trends and potential growth drivers. Components consist of software and services. Deployment mode include cloud, on-premise, and hybrid. Therapeutic areas include cancers, infectious diseases and neurological diseases. End users include pharmaceutical and biotech companies, contract research organizations (CROs), and research and academic institutes.

The report's regional analysis covers North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. It evaluates the impact of AI adoption in clinical trials and the market dynamics, including drivers and challenges. The study concludes with an analysis of leading companies in the market and their product portfolios.

It includes global revenue ($ millions) for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030.

Report Includes

• 56 data tables and 52 additional tables
• In-depth analysis of the global market for artificial intelligence (AI) in pharmaceutical clinical trials
• Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
• Estimates of the market's size and revenue growth prospects, accompanied by a market share analysis by offerings, deployment type, trial phase, therapeutic area, end user and region
• Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
• Impact analysis of U.S. tariff laws on AI in the clinical trials market
• Insights derived from Porter's Five Forces model, as well as a global supply chain analysis
• A look at the regulatory landscape featuring key international and regional regulations and standards for AI adoption
• Evaluation of recent patent activity and key granted and published patents
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Company profiles of major players within the industry, including IQVIA, Medidata, Saama, Merative, and Nvidia Corp.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Future Outlook
• Macroeconomic Factors
• Global GDP Growth
• Demographic Factors
• Impact of U.S. Tariffs
• Porter's Five Forces Analysis
• Impact of AI Adoption on Clinical Trials Market
• Overview
• Use Cases/Case Studies
• Use Case 1: Oncology Patient Recruitment
• Use Case 2: Accelerating Data Processing in Infectious Disease Vaccine Trials
• Use Case 3: Enhancing Patient Retention in Alzheimer's Disease Trials
• AI Adoption: Clinical Trials
• Adoption Trends at Regional/Country Levels
• AI Disruption Trends
• Impact of AI on Industry Verticals
• Impact of AI on the Value Chain
• Market Spending and Investment
• Market Spending and Forecasting Analysis
• Venture Capital Investment in AI Focused on Clinical Trials

Chapter 3 Market Dynamics

• Market Drivers
• Need for a Faster Drug Development Process
• AI-driven Clinical Trials
• Advanced Data Handling for Complex Clinical Input
• Market Restraints
• Data Privacy and Security Concerns
• Regulatory Uncertainties
• High Costs and Technical Complexity
• Market Opportunities
• Accelerated Trials Through Adaptive AI Design
• AI-Augmented Remote Patient Monitoring

Chapter 4 Regulatory Landscape

• Regulatory Framework

Chapter 5 Emerging Technologies

• Overview
• Emerging Technologies
• Machine Learning for Predictive Analytics and Stratification
• Digital Twin Technology
• NLP for Extracting Insights from Unstructured Data
• AI-Powered Trial Design and Optimization
• Blockchain for Secure Clinical Data Management
• Decentralized and Virtual Trial Platforms
• Remote Monitoring Via Wearable Technologies
• Generative AI for Protocol Authoring
• Real-World Evidence Integration in Clinical Trials
• Cloud-based AI Platforms for Scalable Deployment
• Clinical Trial Analysis
• Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for AI in Clinical Trials, by Component
• Takeaways
• Software
• Services
• Global AI in Clinical Trials Market, by Phase
• Takeaways
• Phase III
• Phase II Trials
• Phase I
• Phase IV Clinical Trials
• Global Market for AI in Clinical Trials, by Deployment Mode
• Takeaways
• Cloud
• On-premise
• Hybrid Deployments
• Global Market for AI in Clinical Trials, by Therapeutic Area
• Takeaways
• Oncology
• Infectious Disease Clinical Trials
• Neurological Diseases
• Other Conditions
• Global Market for AI in Clinical Trials, by End User
• Takeaways
• Pharmaceutical and Biotech Companies
• Contract Research Organizations
• Research and Academic Institutes
• Other End Users
• Geographic Breakdown
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Overview

Chapter 8 Sustainability in AI in Clinical Trials: ESG Perspective

• Sustainability Trends and AI Initiatives
• Concluding Remarks

Chapter 9 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• AICURE
• CONCERTAI
• DNANEXUS INC.
• INSILICO MEDICINE
• INTELLIGENCIA AI
• IQVIA
• MEDIDATA
• MERATIVE
• NVIDIA CORP.
• PHESI
• SAAMA
• TEMPUS
• TRINETX LLC
• TRIOMICS
• UNLEARN.AI INC.
• Emerging Start-ups/ Market Disruptors

List of Tables

• Summary Table : Global Market for AI in Clinical Trials, by Region, Through 2030
• Table 1 : Real GDP Growth, by Country, 2022-2025
• Table 2 : Venture Capital Funding for U.S. Companies on AI for Clinical Trials
• Table 3 : VC Investment in AI Focused on Clinical Trials
• Table 4 : Regulations Pertaining to AI in Clinical Trials
• Table 5 : Clinical Trials Studies
• Table 6 : Global Market for AI in Clinical Trials, by Component, Through 2030
• Table 7 : Global Market for AI Software in Clinical Trials, by Region, Through 2030
• Table 8 : Global Market for Services Related to AI in Clinical Trials, by Region, Through 2030
• Table 9 : Global Market for AI in Clinical Trials, by Phase, Through 2030
• Table 10 : Global Market for AI in Phase III Clinical Trials, by Region, Through 2030
• Table 11 : Global Market for AI in Phase II Clinical Trials, by Region, Through 2030
• Table 12 : Global Market for AI in Phase I Clinical Trials, by Region, Through 2030
• Table 13 : Global Market for AI in Phase IV Clinical Trials, by Region, Through 2030
• Table 14 : Global Market for AI in Clinical Trials, by Deployment Mode, Through 2030
• Table 15 : Global Market for Cloud Deployments of AI in Clinical Trials, by Region, Through 2030
• Table 16 : Global Market for On-Premise Deployments of AI in Clinical Trials, by Region, Through 2030
• Table 17 : Global Market for Hybrid Deployments of AI in Clinical Trials, by Region, Through 2030
• Table 18 : Global Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
• Table 19 : Global Market for AI in Oncology Clinical Trials, by Region, Through 2030
• Table 20 : Global Market for AI in Infectious Disease Clinical Trials, by Region, Through 2030
• Table 21 : Global Market for AI in Neurological Disease Clinical Trials, by Region, Through 2030
• Table 22 : Global Market for AI in Clinical Trials for Other Conditions, by Region, Through 2030
• Table 23 : Global Market for AI in Clinical Trials, by End User, Through 2030
• Table 24 : Global Market for AI Used in Clinical Trials by Pharmaceutical and Biotech Companies, by Region, Through 2030
• Table 25 : Global Market for AI Used in Clinical Trials by CROs, by Region, Through 2030
• Table 26 : Global Market for AI Used in Clinical Trials by Research and Academic Institutes, by Region, Through 2030
• Table 27 : Global Market for AI Used by Other End Users in Clinical Trials, by Region, Through 2030
• Table 28 : Global Market for AI in Clinical Trials, by Region, Through 2030
• Table 29 : North American Market for AI in Clinical Trials, by Component, Through 2030
• Table 30 : North American Market for AI in Clinical Trials, by Phase, Through 2030
• Table 31 : North American Market for AI in Clinical Trials, by Deployment Mode, Through 2030
• Table 32 : North American Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
• Table 33 : North American Market for AI in Clinical Trials, by End User, Through 2030
• Table 34 : North American Market for AI in Clinical Trials, by Country, Through 2030
• Table 35 : European Market for AI in Clinical Trials, by Component, Through 2030
• Table 36 : European Market for AI in Clinical Trials, by Phase, Through 2030
• Table 37 : European Market for AI in Clinical Trials, by Deployment Mode, Through 2030
• Table 38 : European Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
• Table 39 : European Market for AI in Clinical Trials, by End User, Through 2030
• Table 40 : European Market for AI in Clinical Trials, by Country, Through 2030
• Table 41 : Asia-Pacific Market for AI in Clinical Trials, by Component, Through 2030
• Table 42 : Asia-Pacific Market for AI in Clinical Trials, by Phase, Through 2030
• Table 43 : Asia-Pacific Market for AI in Clinical Trials, by Deployment Mode, Through 2030
• Table 44 : Asia-Pacific Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
• Table 45 : Asia-Pacific Market for AI in Clinical Trials, by End User, Through 2030
• Table 46 : Asia-Pacific Market for AI in Clinical Trials, by Country, Through 2030
• Table 47 : MEA Market for AI in Clinical Trials, by Component, Through 2030
• Table 48 : MEA Market for AI in Clinical Trials, by Phase, Through 2030
• Table 49 : MEA Market for AI in Clinical Trials, by Deployment Mode, Through 2030
• Table 50 : MEA Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
• Table 51 : MEA Market for AI in Clinical Trials, by End User, Through 2030
• Table 52 : MEA Market for AI in Clinical Trials, by Sub-Region, Through 2030
• Table 53 : South American Market for AI in Clinical Trials, by Component, Through 2030
• Table 54 : South American Market for AI in Clinical Trials, by Phase, Through 2030
• Table 55 : South American Market for AI in Clinical Trials, by Deployment Mode,Through 2030
• Table 56 : South American Market for AI in Clinical Trials, by Therapeutic Area,Through 2030
• Table 57 : South American Market for AI in Clinical Trials, by End User, Through 2030
• Table 58 : South American Market for AI in Clinical Trials, by Country, Through 2030
• Table 59 : Global Ranking of Players in AI in Clinical Trials Industry, 2024
• Table 60 : Strategic Initiatives, 2024 and 2025
• Table 61 : Information Sources Used in Preparing this Report
• Table 62 : Abbreviations Used in this Report
• Table 63 : AiCure: Company Snapshot
• Table 64 : AiCure: Product Portfolio
• Table 65 : AiCure: News/Key Developments, 2022
• Table 66 : ConcertAI: Company Snapshot
• Table 67 : ConcertAI: Product Portfolio
• Table 68 : ConcertAI: News/Key Developments, 2023 and 2024
• Table 69 : DNAnexus Inc.: Company Snapshot
• Table 70 : DNAnexus Inc: Product Portfolio
• Table 71 : DNAnexus Inc: News/Key Developments, 2024 and 2025
• Table 72 : Insilico Medicine: Company Snapshot
• Table 73 : Insilico Medicine: Product Portfolio
• Table 74 : Insilico Medicine: News/Key Developments, 2023-2025
• Table 75 : Intelligencia AI: Company Snapshot
• Table 76 : Intelligencia AI: Product Portfolio
• Table 77 : IQVIA: Company Snapshot
• Table 78 : IQVIA: Financial Performance, FY 2023 and 2024
• Table 79 : IQVIA: Product Portfolio
• Table 80 : IQVIA: News/Key Developments, 2025
• Table 81 : Medidata: Company Snapshot
• Table 82 : Medidata: Product Portfolio
• Table 83 : Medidata: News/Key Developments, 2023-2025
• Table 84 : Merative: Company Snapshot
• Table 85 : Merative: Product Portfolio
• Table 86 : Nvidia Corp.: Company Snapshot
• Table 87 : Nvidia Corp.: Financial Performance, FY 2023 and 2024
• Table 88 : Nvidia Corp.: Product Portfolio
• Table 89 : Nvidia Corp.: News/Key Developments, 2023-2025
• Table 90 : Phesi: Company Snapshot
• Table 91 : Phesi: Product Portfolio
• Table 92 : Phesi: News/Key Developments, 2022-2025
• Table 93 : Saama: Company Snapshot
• Table 94 : Saama: Product Portfolio
• Table 95 : Saama: News/Key Developments, 2023 and 2024
• Table 96 : Tempus: Company Snapshot
• Table 97 : Tempus: Product Portfolio
• Table 98 : Tempus: News/Key Developments, 2022-2025
• Table 99 : TriNetX LLC.: Company Snapshot
• Table 100 : TriNetX LLC: Product Portfolio
• Table 101 : TriNetX LLC: News/Key Developments, 2025
• Table 102 : Triomics: Company Snapshot
• Table 103 : Triomics: Product Portfolio
• Table 104 : Unlearn.ai Inc.: Company Snapshot
• Table 105 : Unlearn.ai Inc.: Product Portfolio
• Table 106 : Unlearn.ai Inc.: News/Key Developments, 2022 and 2025
• Table 107 : Emerging Startups

List of Figures

• Summary Figure : Global Market Shares of AI in Clinical Trials, by Region, 2024
• Figure 1 : Porter's Five Forces Analysis
• Figure 2 : Market Dynamics of Artificial Intelligence in Clinical Trials Market
• Figure 3 : Global Market Shares of AI in Clinical Trials, by Component, 2024
• Figure 4 : Global Market Shares of AI Software in Clinical Trials, by Region, 2024
• Figure 5 : Global Market Shares of Services Related to AI in Clinical Trials, by Region, 2024
• Figure 6 : Global Market Shares of AI in Clinical Trials, by Phase, 2024
• Figure 7 : Global Market Shares of AI in Phase III Clinical Trials, by Region, 2024
• Figure 8 : Global Market Shares of AI in Phase II Clinical Trials, by Region, 2024
• Figure 9 : Global Market Shares of AI in Phase I Clinical Trials, by Region, 2024
• Figure 10 : Global Market Shares of AI in Phase IV Clinical Trials, by Region, 2024
• Figure 11 : Global Market Shares of AI in Clinical Trials, by Deployment Mode, 2024
• Figure 12 : Global Market Shares of Cloud Deployments of AI in Clinical Trials, by Region, 2024
• Figure 13 : Global Market Shares of On-Premise Deployments of AI in Clinical Trials, by Region, 2024
• Figure 14 : Global Market Shares of Hybrid Deployments of AI in Clinical Trials, by Region, 2024
• Figure 15 : Global Market Shares of AI in Clinical Trials, by Therapeutic Area, 2024
• Figure 16 : Global Market Shares of AI in Oncology Clinical Trials, by Region, 2024
• Figure 17 : Global Market Shares of AI in Infectious Disease Clinical Trials, by Region, 2024
• Figure 18 : Global Market Shares of AI in Neurological Disease Clinical Trials, by Region, 2024
• Figure 19 : Global Market Shares of AI in Clinical Trials for Other Conditions, by Region, 2024
• Figure 20 : Global Market Shares of AI in Clinical Trials, by End User, 2024
• Figure 21 : Global Market Shares of AI Used in Clinical Trials by Pharmaceutical and Biotech Companies, by Region, 2024
• Figure 22 : Global Market Shares of AI Used in Clinical Trials by CROs, by Region, 2024
• Figure 23 : Global Market Shares of AI Used in Clinical Trials by Research and Academic Institutes, by Region, 2024
• Figure 24 : Global Market Shares of AI Used by Other End Users in Clinical Trials, by Region, 2024
• Figure 25 : Global Market Shares of AI in Clinical Trials, by Region, 2024
• Figure 26 : North American Market Shares of AI in Clinical Trials, by Country, 2024
• Figure 27 : European Market Shares of AI in Clinical Trials, by Country, 2024
• Figure 28 : Asia-Pacific Market Shares of AI in Clinical Trials, by Country, 2024
• Figure 29 : MEA Market Shares of AI in Clinical Trials, by Sub-Region, 2024
• Figure 30 : South American Market Shares of AI in Clinical Trials, by Country, 2024
• Figure 31 : IQVIA: Revenue Shares, by Business Unit, FY 2024
• Figure 32 : IQVIA: Revenue Shares, by Country/Region, FY 2024
• Figure 33 : Nvidia Corp.: Revenue Share, by Business Unit, FY 2024
• Figure 34 : Nvidia Corp.: Revenue Share, by Country/Region, FY 2024